It was confirmed that proteasome inhibitors have activities against a variety of malignancies.Bortezomib, the first proteasome inhibitor, obtained permission of clinical trial and on sale.

• 研究证实，蛋白酶体抑制剂对许多恶性肿瘤有抗癌活性，第一个获准临床试验和上市的蛋白酶体抑制剂硼替佐米治疗多发性骨髓瘤患者获得了较高的总体有效率和完全缓解率。